Entering text into the input field will update the search result below

StemCells commences efficacy stage in Phase 2 study of neural stem cells

Jun. 04, 2015 11:08 AM ETMicrobot Medical Inc. (MBOT) StockMBOTBy: Douglas W. House, SA News Editor5 Comments
  • StemCells (STEM +1.4%) announces the enrollment its first patient in Cohort 2 of its Phase 2 Pathway Study, designed to assess the efficacy of its HuCNS-SC (purified human neural stem cells) for the treatment of cervical spinal cord injury. Cohort 2 will enroll 40 patients and will constitute the single-blind control arm. The primary endpoint is the change in motor strength from baseline in the upper extremities.
  • The Pathway Study has three cohorts: Cohort 1 is a dose-escalation arm involving six patients, Cohort 2 will assess efficacy in 40 patients and Cohort 3 is an optional open label arm involving six patients with less severe injuries. The trial will follow the participants for one year. Enrollment in Cohort 1 was completed in April.

Recommended For You

About MBOT Stock

SymbolLast Price% Chg
Market Cap
PE
Yield (TTM)
Rev Growth (YoY)
Prev. Close
Compare to Peers

Related Stocks

SymbolLast Price% Chg
MBOT--
Microbot Medical Inc.